Pharmaceutical Firm Sanofi Invests $433M in New Factory

Global biopharmaceutical firm Sanofi plans to build a new manufacturing plant for vaccines at its Sanofi Pasteur Canadian headquarters in Toronto, the firm announced in a press release last Thursday.

Investing CAD$500 million, or about $433 million, in the project, the drug maker said it is expanding its footprint in Canada to increase production of its five-component acellular pertussis (5-acP) antigen.

“Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe,” the head of Sanofi Pasteur and executive vice president David Loew said in a statement. “Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable death.”

Slated for completion in 2021, Sanofi said the facility will also be capable of producing vaccines for diphtheria and tetanus.

“This project is one of the most important investments for the Sanofi global industrial network,” Sanofi Executive Vice President of Global Industrial Affairs Philippe Luscan said in the firm’s release. “It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.”

Click here for information about the upcoming International Powder & Bulk Solids Conference/Exhibition

For more news headlines, articles, and equipment reviews, visit our Equipment Zones